Zai Lab (NASDAQ:ZLAB) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Zai Lab (NASDAQ:ZLAB) to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Zai Lab’s FY2025 earnings at ($1.38) EPS.

Separately, Bank of America reissued a “neutral” rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research note on Monday.

Zai Lab Trading Down 1.4 %

Shares of NASDAQ ZLAB opened at $35.39 on Tuesday. The company’s 50-day moving average price is $28.10 and its 200 day moving average price is $26.25. Zai Lab has a 52 week low of $13.48 and a 52 week high of $36.60. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of -12.78 and a beta of 1.02.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The company had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. As a group, research analysts expect that Zai Lab will post -2.58 earnings per share for the current year.

Insider Activity

In other Zai Lab news, insider Frazor Titus Edmondson III sold 14,544 shares of the business’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $32.98, for a total transaction of $479,661.12. Following the completion of the sale, the insider now owns 14,328 shares of the company’s stock, valued at approximately $472,537.44. The trade was a 50.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ying Du sold 50,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.44, for a total value of $1,622,000.00. Following the sale, the chief executive officer now owns 494,117 shares of the company’s stock, valued at $16,029,155.48. This represents a 9.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 122,127 shares of company stock valued at $4,024,442 in the last 90 days. 13.88% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zai Lab

A number of hedge funds have recently made changes to their positions in ZLAB. GF Fund Management CO. LTD. purchased a new position in Zai Lab in the fourth quarter valued at about $29,000. Pictet Asset Management Holding SA acquired a new stake in shares of Zai Lab in the fourth quarter valued at about $31,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Zai Lab by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock valued at $1,496,000 after buying an additional 1,200 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Zai Lab by 15.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company’s stock worth $290,000 after acquiring an additional 1,502 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Zai Lab by 4.2% in the 4th quarter. Invesco Ltd. now owns 44,340 shares of the company’s stock worth $1,161,000 after acquiring an additional 1,790 shares during the period. Hedge funds and other institutional investors own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.